Nature Communications (Aug 2022)
Effectiveness of REGEN-COV antibody combination in preventing severe COVID-19 outcomes
Abstract
REGEN-COV is a SARS-CoV-2 combined monoclonal antibody treatment which has been shown to be effective in randomised controlled trials. Here, the authors assess its real-world effectiveness using data from Israel during the Delta wave and find that it reduced the risk of hospitalisation, severe disease and death.